Payment overview · 2025
General Payments
$522.81
29 reported records · 16 companies
Healthcare provider profile · identity verified
Philip J Chase, MD
Allopathic & Osteopathic Physicians|Family Medicine · AUBURN, IN · NPI 1225036007
Verified facts
What the public records show
CMS Open Payments records show Philip J Chase, MD received $522.81 in general payments during 2025 across 29 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $92.12 | 17.6% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.81 | 11.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.74 | 9.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $43.93 | 8.4% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.23 | 8.3% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $36.21 | 6.9% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $35.02 | 6.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.38 | 5.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.10 | 4.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.90 | 3.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.24 | 3.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.88 | 3.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.83 | 3.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.46 | 2.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.36 | 2.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.60 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $522.81 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $92.12 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $43.93 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $43.23 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $36.21 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $35.02 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $30.38 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $27.53 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 127 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
163 | 38 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
139 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
127 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
182 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
213 | 51 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 867 | 240 |
| Levothyroxine Sodium | Levothyroxine Sodium | 785 | 194 |
| Omeprazole | Omeprazole | 518 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 506 | 154 |
| Lisinopril | Lisinopril | 484 | 143 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 417 | 118 |
| Metformin Hcl | Metformin Hcl | 370 | 93 |
| Pravastatin Sodium | Pravastatin Sodium | 349 | 95 |
| Carvedilol | Carvedilol | 343 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 318 | 87 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 314 | 86 |
| Losartan Potassium | Losartan Potassium | 275 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 275 | 82 |
| Gabapentin | Gabapentin | 243 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 218 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 217 | 69 |
| Clopidogrel | Clopidogrel Bisulfate | 216 | 66 |
| Eliquis | Apixaban | 213 | 51 |
| Alprazolam | Alprazolam | 192 | 40 |
| Ozempic | Semaglutide | 182 | 28 |
| Trazodone Hcl | Trazodone Hcl | 179 | 51 |
| Metformin Hcl Er | Metformin Hcl | 176 | 56 |
| Furosemide | Furosemide | 175 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 166 | 50 |
| Farxiga | Dapagliflozin Propanediol | 163 | 38 |
| Potassium Chloride | Potassium Chloride | 149 | 46 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 139 | 29 |
| Buspirone Hcl | Buspirone Hcl | 137 | 39 |
| Oxybutynin Chloride | Oxybutynin Chloride | 134 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 40 |
| Meloxicam | Meloxicam | 131 | 42 |
| Sertraline Hcl | Sertraline Hcl | 129 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 128 | 37 |
| Jardiance | Empagliflozin | 127 | 29 |
| Famotidine | Famotidine | 120 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 116 | 26 |
| Glimepiride | Glimepiride | 114 | 27 |
| Donepezil Hcl | Donepezil Hcl | 111 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 111 | 21 |
| Atenolol | Atenolol | 109 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 105 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 103 | 29 |
| Montelukast Sodium | Montelukast Sodium | 100 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 99 | 28 |
| Prednisone | Prednisone | 98 | 79 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 96 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 95 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 93 | 28 |
| Allopurinol | Allopurinol | 92 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 91 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 35 |
| Simvastatin | Simvastatin | 86 | 24 |
| Klor-Con M20 | Potassium Chloride | 84 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 81 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 80 | 19 |
| Tramadol Hcl | Tramadol Hcl | 79 | 24 |
| Aripiprazole | Aripiprazole | 74 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 24 |
| Cephalexin | Cephalexin | 72 | 48 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 72 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 69 | 61 |
| Finasteride | Finasteride | 69 | 21 |
| Naproxen | Naproxen | 67 | 25 |
| Lovastatin | Lovastatin | 66 | 19 |
| Lamotrigine | Lamotrigine | 64 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 61 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 16 |
| Lorazepam | Lorazepam | 60 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 24 |
| Risperidone | Risperidone | 56 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 22 |
| Spironolactone | Spironolactone | 55 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | 12 |
| Synthroid | Levothyroxine Sodium | 52 | 16 |
| Topiramate | Topiramate | 52 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 51 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 16 |
| Nitroglycerin | Nitroglycerin | 50 | 25 |
| Ondansetron Odt | Ondansetron | 49 | 17 |
| Mirtazapine | Mirtazapine | 48 | suppressed |
| Ezetimibe | Ezetimibe | 47 | 16 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | suppressed |
| Baclofen | Baclofen | 44 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 42 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 14 |
| Trulicity | Dulaglutide | 41 | suppressed |
| Valsartan | Valsartan | 41 | 13 |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 12 |
| Valacyclovir | Valacyclovir Hcl | 36 | suppressed |
| Glipizide Er | Glipizide | 35 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 35 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | 11 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | suppressed |
| Glipizide | Glipizide | 33 | 12 |
| Novolog Flexpen | Insulin Aspart | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Cefdinir | Cefdinir | 32 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Olanzapine | Olanzapine | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | 12 |
| Diltiazem 24hr Er | Diltiazem Hcl | 29 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | 12 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 11 |
| Oxycontin | Oxycodone Hcl | 27 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 14 |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 25 | 18 |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Glyburide | Glyburide | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 18 |
| Fluconazole | Fluconazole | 20 | 15 |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | 11 |
| Torsemide | Torsemide | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Cartia Xt | Diltiazem Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Butrans | Buprenorphine | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $522.81 · 29 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AREXVY, Auvelity, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, INGREZZA, INSPIRE, JARDIANCE, LINZESS, NURTEC ODT, QULIPTA, SHINGRIX, TRINTELLIX, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error